Arrowhead Research Corp(NASDAQ:ARWR) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $39.58K. Analysts estimated a revenue of $60.00K. Earnings per share were $-0.32. Analysts had estimated an EPS of $-0.37.
In a different note, Chardan Capital said it Initiates Coverage on Arrowhead Research Corp, according to a research note issued on May 19, 2016. The shares have been rated ‘Buy’ by the firm.
Arrowhead Research Corp (ARWR) made into the market gainers list on Wednesdays trading session with the shares advancing 2.76% or 0.17 points. Due to strong positive momentum, the stock ended at $6.34, which is also near the day’s high of $6.35. The stock began the session at $6.14 and the volume stood at 5,77,219 shares. The 52-week high of the shares is $9.36 and the 52 week low is $3.07. The company has a current market capitalization of $385 M and it has 6,07,50,327 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jan 4, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 23,347 shares at $6.13 per share price.Also, On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price.On Jan 7, 2015, David L. Lewis (Chief Scientific Officer) sold 15,000 shares at $8.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.